CECLOR CD
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Jun 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CECLOR CD is an extended-release oral tablet formulation approved in 1996 by Eli Lilly. The generic name and specific mechanism of action are not available in the provided data. The product represents a small-molecule therapeutic in an oral delivery format.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely in defensive/optimization mode with constrained headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and LOE approaching, opportunities on CECLOR CD are limited and likely focused on defensive brand management and transition planning. Career growth on this asset is constrained; roles emphasize portfolio optimization and generic competition mitigation rather than market expansion.
Brand ManagerField Sales Representative
Worked on CECLOR CD at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.